Astellas

Showing 15 posts of 103 posts found.

Otsuka to take over Astellas’ Cefixime business

June 7, 2019
Medical Communications APIs, Antibiotics, Astellas, Otsuka, antimicrobial, pharma

Japanese firm Otsuka Chemical has bought Astellas Pharma’s antibiotic Cefixime. The agreement gives Otsuka the right to sell Cefixime and …

shutterstock_159488225

Astellas and Cytokinetics’ reldesemtiv falls short at Phase 2 in ALS

May 7, 2019
Manufacturing and Production, Sales and Marketing Astellas, als, amyotrophic lateral sclerosis, cytokinetics, pharma

Cytokinetics has announced at the American Academy of Neurology (AAN) that its fast skeletal muscle troponin activator (FSTA) reldesemtiv fell …

top_10_image

Top Ten most popular articles on Pharmafile.com this week!

April 12, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, BMS, Eisai, Gilead, MSD, Pfizer, ViiV, indivior

This week was an excellent week for recommendations and approvals after Eisai, MSD, Pfizer, BMS and ViiV scored wins. Meanwhile …

NICE turns down Astellas’ Xtandi in prostate cancer

April 8, 2019
Research and Development, Sales and Marketing Astellas, Cancer, NHS, NICE, UK, pharma, prostate cancer

Astellas’ Xtandi (enzalutamide) has been rejected by UK medicines watchdog NICE for use on the NHS as a therapy for …

Astellas’ Xtandi “significantly improves” progression-free survival in advanced hormone-sensitive prostate cancer

February 18, 2019
Research and Development, Sales and Marketing Astellas, Cancer, Xtandi, pharma, prostate cancer

Japanese pharma firm Astellas has lifted the curtain on new data for its androgen receptor signalling inhibitor Xtandi (enzalutamide), when …

Astellas’ Xospata becomes US-approved drug for FLT3-mutated acute myeloid leukaemia

November 29, 2018
Sales and Marketing Astellas, FDA, US, Xospata, acute myeloid leukamia

Astellas has revealed that Xospata (gilteritinib) has been awarded FDA approval as a treatment for relapsed or refractory acute myeloid …

Astellas’ chronic kidney drug shows superiority at Phase 3

September 20, 2018
Research and Development Astellas, chronic kidney disease, pharma, roxadustat

Astellas has revealed new Phase 3 data for roxadustat in the treatment of chronic kidney disease (CKD) in patients with …

Astellas acquires gene therapy group Quethera in £85 million deal

August 13, 2018
Sales and Marketing Astellas, Japan, gene therapy, ocular, quethera, vision

The Japanese company Astellas Pharma has acquired British gene therapy group Quethera in a deal worth up to £85 million. …

FDA expands Pfizer and Astellas’ Xtandi into castration-resistant prostate cancer

July 16, 2018
Sales and Marketing Astellas, Cancer, FDA, Pfizer, US, Xtandi, pharma, prostate cancer

Astellas and Pfizer have revealed that their androgen receptor inhibitor Xtandi (enzalutamide) has received approval from the FDA to expand …

4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

May 25, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, Cancer, Gielad, Novartis, brexit, obesity, pharma, top ten

It’s a special Firday here in Europe, as today marks the advent of the General Data Protection Regulation (GDPR), an …

astellas_tokyo_copy

Astellas begins major restructure, as 600 jobs slashed

May 24, 2018
Medical Communications Astellas, biotech, drugs, pharma, pharmaceutical

Astellas, under the direction of new CEO, Kenji Yasukawa, has unveiled a major new restructure, ahead of a difficult looking …

Seattle Genetics gain breakthrough therapy designation

March 26, 2018
Manufacturing and Production, Sales and Marketing Astellas, Seattle Genetics, biotech, drugs, pharma, pharmaceutical

Seattle Genetics and Astellas have confirmed that the drug candidate they are co-developing, enfortumab, has been given FDA breakthrough therapy …

Astellas scoops up Universal Cells for $102.5m

February 15, 2018
Sales and Marketing Astellas, Universal Cells, biotech, drugs, pharma, pharmaceutical

Astellas Pharma had only signed an exclusive licensing deal with Universal Cells back in October for the co-development of a …

kenji

Astellas confirms Kenji Yasukawa as new President and CEO

February 7, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, appointment

Japanese pharmaceutical firm Astellas has announced that its Board of Directors has approved the selection of current Chief Strategy Officer …

Pfizer receives prostate cancer drug boost with trial results

September 15, 2017
Medical Communications, Research and Development Astellas, Pfizer, Xtandi, biotech, drugs, pharma, pharmaceutical

Pfizer, and its partner Astellas Pharma, received a major boost to its plans for prostate cancer treatment, Xtandi, by announcing …

The Gateway to Local Adoption Series

Latest content